UPSTREAM BIO, INC. Retained Earnings
UPSTREAM BIO, INC. (UPB) had Retained Earnings of -$414.52 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-11
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$414.52M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$374.81M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$334.22M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$291.76M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$414.52M 10-Q · filed 2026-08-11 |
| 2026-03-31 | -$374.81M 10-Q · filed 2026-05-13 |
| 2025-12-31 | -$334.22M 10-Q · filed 2026-08-11 |
| 2025-09-30 | -$291.76M 10-Q · filed 2025-11-05 |
| 2025-06-30 | -$258.02M 10-Q · filed 2025-08-06 |
| 2025-03-31 | -$218.05M 10-Q · filed 2025-05-06 |
| 2024-12-31 | -$190.78M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$169.54M 10-Q · filed 2024-11-07 |
| 2023-12-31 | -$127.97M 10-K · filed 2025-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |